Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder

Journal of Clinical Psychiatry

Volumn 75, Issue 3, 2014, Pages 238-245

  Kemp, David E ^a   Zhao, Jun ^a   Cazorla, Pilar ^a   Landbloom, Ronald P ^a   Mackle, Mary ^a   Snow Adami, Linda ^a   Szegedi, Armin ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASENAPINE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; BIPOLAR DISORDER; BIPOLAR MANIA; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG WITHDRAWAL; HUMAN; METABOLIC DISORDER; POST HOC ANALYSIS; PRIORITY JOURNAL; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, LDL; CONTROLLED CLINICAL TRIALS AS TOPIC; FEMALE; HEMATOLOGIC TESTS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; TREATMENT OUTCOME; TRIGLYCERIDES; WEIGHT GAIN;

EID: 84898740332     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.12m08271     Document Type: Article

References (45)

1. Laursen TM, Munk-Olsen T, Gasse C. Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder. PLoS ONE. 2011;6(9):e24597.
2. Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ. 2011;343:d5422.
3. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3(2):A42.
4. Arango C, Bobes J, Aranda P, et al; CLAMORS Study Collaborative Group. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res. 2008;104(1-3):l-12.
5. Thompson KN, Phillips LJ, Komesaroff P, et al. Stress and HPA-axis functioning in young people at ultra high risk for psychosis. Psychiatr Res. 2007;41(7):561-569.
6. Kemp DE, Gao K, Chan PK, et al. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord. 2010;12(4):404-413.
7. Pariante CM, Dazzan P, Danese A, et al. Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacobgy. 2005;30(10):1923-1931.
8. Dasgupta A, Singh OP, Rout JK, et al. Insulin resistance and metabolic profile in antipsychotic naive schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1202-1207.
9. Guest PC, Schwarz E, Krishnamurthy D, et al. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology. 2011;36(7): 1092-1096.
10. Rush AJ, Giles DE, Schlesser MA, et al. The dexamethasone suppression test in patients with mood disorders. Clin Psychiatry. 1996;57(10):470-484.
11. Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: a review. Clin Psychiatry. 2006;67(7):1034-1041.
12. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51(8):480-491.
13. Megna JL, Schwartz TL, Siddiqui UA, et al. Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions. Ann Clin Psychiatry. 2011;23(2):131-140.
14. Le Hellard S, Theisen FM, Haberhausen M, et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiatry. 2009;14(3):308-317.
15. Oresic M, Tang J, Seppanen-Laakso T, et al. Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med.2011;3(3):19.
16. Kaddurah-Daouk R, McEvoy J, Baillie RA, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007;12(10): 934-945.
17. Kemp DE, Karayal ON, Calabrese JR, et al. Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles. Eur Neuropsychopharmacol. 2012;22(2):123-131.
18. Kemp DE, Calabrese JR, Tran QV, et al. Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Psychiatry. 2010;71(9):1138-1144.
19. van Winkel R, van Os J, Celic I, et al. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. Clin Psychiatry. 2008;69(8):1319-1327.
20. Birkenaes AB, Opjordsmoen S, Brunborg C, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. Clin Psychiatry. 2007;68(6):917-923.
21. Kilbourne AM, Brar JS, Drayer RA, et al. Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Psychosomatics. 2007;48(5):412-417.
22. Gerrits MG, de Greef R, Dogterom P, et al. Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations. Clin Pharmacol. 2012;52(5):757-765.
23. Shahid M, Walker GB, Zorn SH, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. JPsychopharmacol. 2009;23(1):65-73.
24. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo-and risperidone-controlled trial. Clin Psychiatry. 2007;68( 10): 1492-1500.
25. Mclntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11(7):673-686.
26. Mclntyre RS, Cohen M, Zhao J, et al. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009;11(8):815-826.
27. Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30(2):106-115.
28. Mclntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010;122(1-2):27-38.
29. Mclntyre RS, Cohen M, Zhao J, et al. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord. 2010;126(3):358-365.
30. Schoemaker J, Naber D, Vrijland P, et al. Long-term assessment of asenapine vs olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43(4):138-146.
31. Kane JM, Mackle M, Snow-Adami L, et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. Clin Psychiatry. 2011;72(3):349-355.
32. Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. Clin Psychopharmacol. 2012;32(1):36-45.
33. Study 041021. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine positive control in subjects with an acute exacerbation of schizophrenia. http://dinicaltrials.gov/ct2/show/NCT00156117?term=NCT0 0156117&rank=l. Updated October 9,2009. Accessed August 21,2013.
34. Study 041022. A multicenter, randomized, double-blind, flexible-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine positive control in subjects with an acute exacerbation of schizophrenia. http://dinicaltrials.gov/ct2/show/study/NCT00151424?term= NCT00151424&rank=l. Updated August 25,2008. Accessed August 21,2013.
35. Study 041512. A multicenter, randomized, double-blind, flexible-dose, long-term extension trial of the safety and maintenance of effect of asenapine using olanzapine positive control in subjects who complete protocols 041021 or 041022. http://dinicaltrials.gov/ct2/show/study/NCT00156091?intr=%22A senapine%22&rank=34. Updated October 2,2009. Accessed August 21,2013.
36. Study 25520. Long-term efficacy and safety evaluation of asenapine (10-20 mg/day) in subjects with schizophrenia or schizoaffective disorder, in a multicenter trial using olanzapine (10-20 mg/day) as a control. http://www. dinicaltrials.gov/ct2/show/NCT00212771?term=P05846&rank=l. Updated October 2,2009. Accessed August 21,2013.
37. Study A41012. A single-center randomized, double-blind, placebo-controlled, titration study to evaluate the tolerability of sublingual org 5222 up to 20 mg twice daily in subjects with schizophrenia or schizoaffective disorder, http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2009/022117s000-ClinPharmR-P2.pdf. Accessed August 21,2013.
38. Chapel S, Hutmacher MM, Haig G, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol. 2009;49(11):1297-1308.
39. MedDRA MSSO. Medical Dictionary for Regulatory Activities. http://www. meddra.org/faq. Accessed August 21,2013.
40. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drags. 2007;21(11):911-936.
41. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(3):CD006654.
42. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68(1):29-39.
43. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003;28(suppl 1):83-96.
44. Stahl SM. The serotonin-7 receptor as a novel therapeutic target. Clin Psychiatry. 2010;71(11):1414-1415.
45. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. Clin Psychiatry. 2007; 68(suppl 1):20-27.